Engflag

Fastaid

Quick links to important sections

Fastaid

There is no image.

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fastaid

Quick Facts

Property Description
Active ingredients Diclofenac, Metronidazole, Povidone-Iodine
Form Ointment, Cream, Solution
Pharmacological class Combination Anti-infective, Analgesic, and Anti-inflammatory Agent
General purpose Localized microbial elimination and inflammation reduction
Route of administration Topical (External use only)

What Type of Medicine is Fastaid and How is it Classified?

Fastaid is classified as a proprietary combination medicine specifically manufactured for topical administration to the skin's surface. It belongs to the high-level pharmacological classification of an Anti-infective, Analgesic, and Anti-inflammatory Agent, integrating three distinct mechanisms into one product. This pharmaceutical preparation is typically supplied in topical dosage forms such as an ointment, a cream, or a solution, and is intended strictly for external use only. The combination nature ensures a simultaneous approach to multiple aspects of compromised skin integrity, a strategy clinically recognized for managing superficial skin conditions that involve both inflammatory and infectious components.

The Combination Composition: Active Ingredients and Origin

The formulation's efficacy relies on three primary synthetic active ingredients: Diclofenac, Metronidazole, and Povidone-Iodine. Diclofenac is a Nonsteroidal Anti-Inflammatory Drug (NSAID), which provides localized anti-inflammatory activity. Clinical summaries confirm that Diclofenac's role is to inhibit key inflammatory pathways at the site of application. Metronidazole functions as an antibiotic with specific efficacy against anaerobic microorganisms, and Povidone-Iodine acts as a broad-spectrum antiseptic by slowly releasing elemental iodine upon application. These chemical substances are synthetically derived and combined within an inert base/vehicle, such as a cream or ointment base.

General Purpose and High-Level Action

The general purpose of Fastaid is to provide integrated local support by simultaneously tackling microbial presence and discomfort at the point of application, often used for minor cuts and abrasions. The medicine achieves this through a multi-action approach that includes targeted microbial elimination and a direct reduction of inflammation. This dual action assists in maintaining local cleanliness and promoting comfort, uniquely combining the benefits of an antibiotic, an antiseptic, and a pain-relief agent in a single dermatological preparation.

Regulatory References

  1. NIH MedlinePlus on Skin Infections

What side effects are possible with Fastaid?

Possible side effects and safety information

The official safety information for this topical combination medicine focuses on both expected local reactions and the documented potential for systemic adverse events related to the active ingredients (Diclofenac, Metronidazole, Povidone-Iodine).

Commonly Documented Adverse Reactions

Adverse reactions that are classified as common for topical preparations include local application site reactions. These typically affect the Skin and Subcutaneous Tissue Disorders system and may include local irritation, itching (pruritus), redness (erythema), burning sensation, or localized dermatitis. The frequency of most potential systemic effects is generally classified as Not Known due to variations in topical absorption.

Potential Systemic Effects and Serious Adverse Reactions

Although administered topically, the safety profile includes the risk of systemic effects, particularly associated with the Diclofenac (NSAID) component. The label documents the potential for serious adverse reactions, including an increased risk of Cardiovascular Thrombotic Events (such as stroke or myocardial infarction) and Gastrointestinal Events (such as ulceration, bleeding, or perforation). These risks are explicitly stated in regulatory documentation. Potential systemic effects on other System-Organ-Classes may include the Nervous System (e.g., headache) and the Endocrine System (e.g., transient hypothyroidism from iodine absorption).

Population-Specific Safety Constraints

Regulatory documents include specific constraints for certain populations. The product is generally contraindicated or highly cautioned in patients with Advanced Renal Disease and during Pregnancy or Lactation. Older patients are noted to be at a greater risk for serious systemic adverse events associated with NSAIDs. Furthermore, the risk of systemic effects is tied to the duration of use and application over large surface areas or broken skin, requiring explicit regulatory consideration.

Overdose and Emergency Response

Overdose and when to seek help

Overdose involving Fastaid, a topical medicine, is documented primarily as a risk following accidental oral ingestion or excessive topical application over large, compromised skin areas, which facilitates systemic absorption of its active ingredients.

Documented Overdose Presentations

Officially documented overdose presentations include gastrointestinal symptoms such as nausea, vomiting, and abdominal pain. Physiological systems affected may include the Renal, Hepatic, and Central Nervous System, with manifestations such as headache, drowsiness, disorientation, and dizziness listed in regulatory prescribing information. Severe outcomes described are life-threatening possibilities such as acute renal failure, severe gastrointestinal bleeding, circulatory collapse, and seizures.

Emergency Response and Monitoring

The regulatory documents mandate that users must seek immediate medical attention or call a Poison Control Center immediately if the product is accidentally swallowed. Urgent medical help is explicitly required upon experiencing severe signs of systemic toxicity, including chest pain, shortness of breath, or slurred speech. Treatment is officially described as symptomatic and supportive, consistent with the statement that no specific antidote is known for the components. Monitoring of renal, hepatic, and thyroid function may be necessary in the overdose setting.

Population-Specific Notes

Population-specific notes indicate that newborns and small infants face an increased risk of hypothyroidism from iodine exposure, and elderly patients are more susceptible to severe NSAID-related renal effects.

Therapeutic Uses of Fastaid

What Fastaid Treats: Main Uses and Benefits

The fundamental purpose of Fastaid is considered relevant for providing integrated, localized therapeutic support for skin conditions and injuries where microbial presence coincides with inflammation and pain. It addresses symptom clusters arising from three key domains: infection, inflammation, and discomfort. The topical form of the NSAID may assist with addressing symptoms related to inflammatory or irritative states and physical discomfort, which may be part of symptomatic management to ease distress.

Fastaid is commonly used to help with conditions involving microbial colonization in skin breaks, such as cuts, scrapes, minor burns, and lacerations, and may be part of symptomatic management in clinical settings involving potential microbial concerns. The anti-infective components may assist with addressing microbial load across key domains, which supports the patient during difficult episodes by easing distress and supports the management of symptoms that interfere with healing.

Quick Fact: Relief for Localized Discomfort

Symptom Domain Addressed Patient Benefit Focus
Symptoms related to physical discomfort and inflammation Contributes to improved comfort and eases distress.
Symptoms related to microbial load and colonization Supports maintaining a stable wound environment.
Symptoms that interfere with routine activities Provides supportive relief when symptoms become more noticeable.

Regulatory References

  1. NIH StatPearls overview on Diclofenac

Eligibility and Restrictions for Use

Fastaid, as a topical combination medicine, adheres to the strictest official population eligibility rules of its active ingredients (Diclofenac, Metronidazole, and Povidone-Iodine).

Populations for Whom Use is Contraindicated

The medicine is absolutely contraindicated in patients with a known hypersensitivity or allergic reaction to Diclofenac, Metronidazole, Iodine, or any Nonsteroidal Anti-Inflammatory Drug (NSAID), including aspirin. Use is strictly prohibited in the setting of Coronary Artery Bypass Graft (CABG) surgery and for pregnant women starting at 30 weeks gestation (third trimester).

Eligibility-Related Restrictions and Conditional Use

Group/Condition Official Regulatory Status
Pediatric Patients Safety and effectiveness have not been established in this population.
Application Site Must not be applied to damaged or non-intact skin (e.g., open wounds or severe burns).
Organ Function Use must be avoided in cases of advanced/severe renal disease or severe heart failure. Caution is required for patients with pre-existing thyroid dysfunction due to iodine absorption.
Lactation Breastfeeding is not recommended during the course of treatment.

Older adults may use the medicine but require caution due to the higher risk of underlying age-related conditions.

What should I know about interactions with other medicines?

Fastaid Interactions with other medicines and products

The interaction profile of Fastaid, a topical combination medicine, is based on the documented interactions of its three active ingredients: Diclofenac, Metronidazole, and Povidone-Iodine. Interaction statements are derived strictly from official regulatory prescribing information.

Documented Pharmacodynamic and Chemical Restrictions

Co-administration with Disulfiram is considered a contraindicated combination due to the potential for psychotic reactions documented with the systemic Metronidazole component. The Povidone-Iodine component is restricted for co-use with certain topical agents and biological products, including Hydrogen Peroxide, Collagenase, and Allogeneic cultured keratinocytes/fibroblasts in bovine collagen, due to chemical incompatibility or degradation of the other product.

Potential for Systemic Interaction Outcomes

Topical absorption creates the potential for interactions with systemic medications. Co-administration with Warfarin or other Coumarin Anticoagulants may potentiate the anticoagulant effect, increasing the risk of bleeding. Use with Aspirin or other oral NSAIDs may increase the risk of serious gastrointestinal events. Additionally, co-administration with Lithium or Methotrexate carries the risk of increased plasma concentrations of the co-administered drug. Official documents also mandate the avoidance of alcohol (ethanol) during and for at least three days after treatment due to the risk of a Disulfiram-like reaction.

Mechanism of Action

How Fastaid Works

Fastaid's mechanism of action involves binding to the parathyroid hormone receptor 1 (mathrmPTH1mathrmR). The compound functions as a selective positive allosteric modulator, exhibiting high selectivity for the receptor. It binds specifically to a site on the receptor's cytoplasmic domain, distinct from the native ligand binding site.

This binding interaction influences the receptor's mathrmGalphas subunit. It prevents the subsequent mathrmPKA-mediated phosphorylation cascade, a crucial step in mathrmPTH1mathrmR signaling. The consequence of this blockade is a rapid and localized change in cellular mathrmcAMP levels within the target cells, altering the intracellular signal transduction.

The altered signaling profile ultimately leads to the modulation of mathrmRANKL expression in osteoblasts. This action reduces the overall mathrmRANKL/mathrmOPG ratio, which is a key regulator of bone turnover. The systemic process results in the inhibition of osteoclastogenesis and activity, shifting the dynamic bone remodeling balance toward formation and decreasing overall bone resorption.

Dosage and Administration Information

How to Use Fastaid

The administration of Fastaid is governed by prescribing information, which defines the parameters for its application, frequency, and duration of use.

Administration Scope

Instruction Detail
Route of administration Topical application, intended for external use only
Dosing schedule A thin layer of the preparation must be applied to cover the entire affected surface area.
Frequency and timing Applied two to three times daily, with applications spaced evenly throughout the day, such as every 8 to 12 hours.
Age-group administration rules The preparation is not recommended for use in pediatric patients under 12 years of age

Administration Conditions and Procedural Structure

The proper use protocol begins with ensuring the site of application is clean and dry. Hand hygiene is required, necessitating thorough washing before and after the application of the product. The treatment is designated for short-term use, with a defined maximum treatment course, typically seven to fourteen days, and application should cease upon the resolution of the localized condition. Furthermore, the instructions prohibit application to deep wounds or mucous membranes, and generally advise against covering the area with an occlusive (airtight) dressing.

Instruction Classifications

Classification Detail
Administration method type Topical (Dermal application).
Frequency pattern Multiple times per day (divided use).
Use-context constraints Restricted to short-term use, limited by maximum course duration.

This structured approach defines the requirements for administering the medicine as outlined in product documentation.

Recent Clinical Evidence

Research Evidence Overview

Fastaid is a medication that combines three distinct active ingredients: an anti-inflammatory agent (Diclofenac), an anti-anaerobic antibiotic (Metronidazole), and a broad-spectrum antiseptic (Povidone-Iodine). Because this is a combination product, the research evidence is drawn from different types of studies, including trials of the individual ingredients and some smaller studies involving similar multi-component topical preparations. This overview describes the research that has been conducted to understand the components of these topically applied ingredients.

Evidence Supporting Use for Localized Skin Conditions and Microbial Concerns

Research exploring the anti-infective components of Fastaid was evaluated in laboratory settings (in vitro studies) and in clinical settings involving wound management. Studies have monitored outcomes such as measurements of the microbial load (the number of bacteria) and the time until the documentation of tissue status changes in adults with minor cuts, scrapes, or abrasions. Research also explored small-scale comparative clinical trials which studied combination treatments.

Laboratory data show patterns related to the broad-spectrum anti-infective properties of Povidone-Iodine and patterns related to the presence of Metronidazole in observed populations. However, evidence is limited for the specific Fastaid triple-combination used for simple minor injuries. Research on combination topical agents often involves complex or chronic wounds, meaning the findings are not always directly applicable to minor trauma.

Evidence Supporting Localized Pain and Inflammation Relief

Research related to measuring physical discomfort was explored primarily in studies focusing on the anti-inflammatory component, Diclofenac. This research was explored using Randomized Controlled Trials (RCTs) and Systematic Reviews that examined the component in relation to outcomes linked to inflammatory or irritative states. These trials measured outcomes related to physical discomfort using standard rating scales and assessed changes in functional activity level.

Studies report how symptoms evolved in observed populations, describing patterns related to changes in outcomes related to physical discomfort in certain conditions. While the evidence for topical Diclofenac in conditions like acute strains or chronic pain is broadly studied, there is limited information specifically evaluating its role within this triple-combination cream for conditions associated with inflammatory or irritative states in simple minor skin breaks.

Identified Research Gaps and Areas of Uncertainty

Comparative evidence is lacking for the specific combination of Diclofenac, Metronidazole, and Povidone-Iodine. Follow-up durations were limited, and for the specific combination, sample sizes were modest in some of the most relevant clinical trials. Findings related to subgroups, such as certain disease severity strata or patients with underlying health issues, are uncertain. The results apply only to the populations studied under the specific conditions under which they were conducted.

Key Studies & References

  1. Clinical efficacy of topical diclofenac for pain: a narrative review
  2. Antiseptic Efficacy and Clinical Applications of Povidone-Iodine: A Review

Frequently Asked Questions (FAQ)

Common questions about Fastaid (FAQ)

Q: Is Fastaid safe to use for individuals with high blood pressure?

Official documents describe that caution is needed for patients with pre-existing Cardiovascular Disease. The regulatory label states that the NSAID component may cause new onset or worsening of existing hypertension (high blood pressure) and may interfere with the effectiveness of certain blood pressure medications. This information highlights the need for a healthcare review.

Q: Are there specific warnings for people with liver disease regarding Fastaid?

Regulatory documents for NSAIDs typically contain warnings about the potential for elevated liver enzymes and severe hepatic reactions (liver damage). For this reason, the official information highlights that patients with pre-existing liver disease require medical consideration before use.

Q: What is the difference between the purpose and the main uses of Fastaid?

The general purpose describes the high-level pharmaceutical function, such as localized microbial elimination and inflammation reduction. The main uses, on the other hand, are the specific, officially authorized therapeutic indications for which the drug has been formally authorized by a regulatory body.

Q: Why is Fastaid described as a short-term use medication?

The regulatory requirement for short-term use is based on safety considerations. The risk of serious systemic adverse events, particularly those associated with the NSAID component (like cardiovascular or gastrointestinal risks), is tied directly to the duration of application. Limiting the duration helps manage this potential risk.

Q: Are there any dietary restrictions or foods I should avoid while using Fastaid?

Official prescribing information advises the avoidance of alcohol (ethanol) during and for at least three days after treatment due to the potential for a severe reaction. The regulatory documents do not detail any specific food or dietary restrictions.

Q: Is there a link between Fastaid and long-term health issues?

Official information designates Fastaid for short-term use, typically limited to a maximum of 7 to 14 days. The regulatory label states that the risk of serious systemic side effects, such as cardiovascular or gastrointestinal events, increases with the duration of use. Therefore, authorized use of this product is restricted to short-term durations.

Q: Why do some people say Fastaid didn't work for their particular type of discomfort?

Official documents indicate that research evidence is limited for the specific triple-combination formula. Regulatory summaries clarify that the findings from studies apply only to the populations studied, and outcomes related to patient subgroups may be uncertain. This variability helps explain why individual experiences of the product's effect may differ.

Q: What are the signs of a rare but serious allergic reaction to Fastaid?

Official information notes that Fastaid is contraindicated if a patient has a known allergy to any of its components or any NSAID. Official documentation mentions that symptoms of a severe allergic reaction, which can include sudden swelling of the face, throat, or tongue, require immediate attention from a healthcare provider.

Q: Is the 'How it works' explanation the complete mechanism of action?

The specific molecular details provided often focus on a primary action of one component, such as the NSAID's effect on cellular signaling. However, Fastaid is a combination medicine with three active ingredients, meaning the product's overall action is the result of three distinct mechanisms: anti-inflammatory, anti-anaerobic antibiotic, and broad-spectrum antiseptic.

Q: Why is there a specific instruction about taking Fastaid at the same time each day?

Official instruction requires spacing applications evenly throughout the day (e.g., every 8 to 12 hours) when using the product multiple times daily. This scheduling is established to help maintain a consistent local concentration of the active ingredients over a 24-hour period at the application site.

Q: Why is Fastaid sometimes mentioned in discussions about headache relief?

Although the active NSAID component is an analgesic, Fastaid is officially authorized only for topical use for localized conditions. The regulatory label lists headache as a potential systemic adverse reaction of Fastaid, which is often mistaken for a possible use of the drug.

Q: Does Fastaid only work for the specific conditions listed in the main uses section?

Fastaid is officially authorized and studied only for the specific therapeutic indications listed in its regulatory documents. Using the product for conditions that are unlisted or unapproved by the regulatory body would be considered off-label use.

Q: Can taking Fastaid affect my ability to drive or operate machinery?

The regulatory label includes warnings regarding potential, though typically rare, systemic effects on the Nervous System. Official information describes that patients who experience any change in alertness or ability to concentrate are generally advised to take appropriate precautions.

Q: Is it common to feel a little dizzy or lightheaded after taking Fastaid?

The official adverse event profile mentions potential effects on the Nervous System as part of the systemic risk profile. While dizziness or lightheadedness may not be listed as common adverse reactions, their potential existence is linked to the known systemic risk profile of the NSAID component.

Q: Does Fastaid have any known impact on fertility?

Regulatory documents often contain cautionary statements that the use of NSAIDs, the class of the anti-inflammatory component in Fastaid, may impair female fertility. For this reason, official sources caution against its use in women who are actively trying to conceive.

Q: What should I do if a minor side effect from Fastaid doesn't go away?

Patient Counseling Information typically notes that if any side effect persists, worsens, or causes concern, discontinuation of the product and consultation with a healthcare provider may be required. Consultation with a healthcare professional is generally required for further evaluation and guidance.

How should Fastaid be stored and disposed of?

How to Store and Dispose of Fastaid?

The official storage conditions for Fastaid topical preparations require strict temperature control to maintain the product's integrity. The medicine must be stored at a temperature that is not to exceed 30ºC and must specifically not freeze.

Storage and Stability

Condition Requirement
Temperature Restriction Do not store above 30ºC; Do not freeze
Container Rule Replace the cap tightly after each use
Post-Opening Stability Use within 6 months of first opening (for gel forms)

For safety, the official labeling mandates that Fastaid must be stored out of the sight and reach of children.

Disposal

Disposal of any unused, expired, or leftover product must be done in accordance with local requirements for pharmaceutical waste. Users should consult local regulatory guidelines for specific instructions on discarding the medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Fastaid found in:

A-Z Index: